Efficacy, safety and administration timing of trastuzumab in human epidermal growth factor receptor 2 positive breast cancer patients: A meta-analysis

Trastuzumab has been demonstrated to be an effective treatment in patients with human epidermal growth factor receptor-2 (HER-2) positive breast cancer (BC); however, inconsistent results with regards to the long-term survival benefits, safety and optimal administration timing of trastuzumab exist....

Descripción completa

Detalles Bibliográficos
Autores principales: CHEN, YUAN-YUAN, WANG, LIN-WEI, CHEN, FANG-FANG, WU, BI-BO, XIONG, BIN
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840704/
https://www.ncbi.nlm.nih.gov/pubmed/27168794
http://dx.doi.org/10.3892/etm.2016.3095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840704/
https://www.ncbi.nlm.nih.gov/pubmed/27168794
http://dx.doi.org/10.3892/etm.2016.3095

Ejemplares similares